Companies › Viking Therapeutics
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 1; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VK2735 GLP-1 and GIP dual agonist | GLP1R, GIPR | Phase 3 | Weight Loss; Obese Adults | May 2027 |
| VK3019 GLP-1 receptor agonist | – | Phase 1 | Obese Adults | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07846033 | VK3019 | Phase 1 | Obese Adults | Metabolic and endocrine | Nov 2026 |
| NCT07838740 | VK2735 | Phase 1 | Obese Adults | Metabolic and endocrine | May 2027 |
| NCT07104500 | VK2735 | Phase 3 | Weight Loss | Metabolic and endocrine | Jul 2027 |
| NCT07104383 | VK2735 | Phase 3 | Weight Loss | Metabolic and endocrine | Jul 2027 |
Cash and short-term investments of $960m on 2026-09-30; operating cash outflow about $506m a year; runway about 23 months at that burn, to Aug 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Beijing QL Biopharmaceutical Chendu DIAO Pharmaceutical Group Amylyx Pharmaceuticals Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Medicure
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.